Cargando…

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide, particularly in China. Despite the development of HCC treatment strategies, the survival rate remains unpleasant. Gene-targeted oncolytic viral therapy (GTOVT) is an emerging treatment modality—a kind of cancer-targeted th...

Descripción completa

Detalles Bibliográficos
Autores principales: Abudoureyimu, Mubalake, Lai, Yongting, Tian, Chuan, Wang, Ting, Wang, Rui, Chu, Xiaoyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857090/
https://www.ncbi.nlm.nih.gov/pubmed/31781493
http://dx.doi.org/10.3389/fonc.2019.01182
_version_ 1783470695098875904
author Abudoureyimu, Mubalake
Lai, Yongting
Tian, Chuan
Wang, Ting
Wang, Rui
Chu, Xiaoyuan
author_facet Abudoureyimu, Mubalake
Lai, Yongting
Tian, Chuan
Wang, Ting
Wang, Rui
Chu, Xiaoyuan
author_sort Abudoureyimu, Mubalake
collection PubMed
description Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide, particularly in China. Despite the development of HCC treatment strategies, the survival rate remains unpleasant. Gene-targeted oncolytic viral therapy (GTOVT) is an emerging treatment modality—a kind of cancer-targeted therapy—which creates viral vectors armed with anti-cancer genes. The adenovirus is a promising agent for GAOVT due to its many advantages. In spite of the oncolytic adenovirus itself, the host immune response is the determining factor for the anti-cancer efficacy. In this review, we have summarized recent developments in oncolytic adenovirus engineering and the development of novel therapeutic genes utilized in HCC treatment. Furthermore, the diversified roles the immune response plays in oncolytic adenovirus therapy and recent attempts to modulate immune responses to enhance the anti-cancer efficacy of oncolytic adenovirus have been discussed.
format Online
Article
Text
id pubmed-6857090
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68570902019-11-28 Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC Abudoureyimu, Mubalake Lai, Yongting Tian, Chuan Wang, Ting Wang, Rui Chu, Xiaoyuan Front Oncol Oncology Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide, particularly in China. Despite the development of HCC treatment strategies, the survival rate remains unpleasant. Gene-targeted oncolytic viral therapy (GTOVT) is an emerging treatment modality—a kind of cancer-targeted therapy—which creates viral vectors armed with anti-cancer genes. The adenovirus is a promising agent for GAOVT due to its many advantages. In spite of the oncolytic adenovirus itself, the host immune response is the determining factor for the anti-cancer efficacy. In this review, we have summarized recent developments in oncolytic adenovirus engineering and the development of novel therapeutic genes utilized in HCC treatment. Furthermore, the diversified roles the immune response plays in oncolytic adenovirus therapy and recent attempts to modulate immune responses to enhance the anti-cancer efficacy of oncolytic adenovirus have been discussed. Frontiers Media S.A. 2019-11-08 /pmc/articles/PMC6857090/ /pubmed/31781493 http://dx.doi.org/10.3389/fonc.2019.01182 Text en Copyright © 2019 Abudoureyimu, Lai, Tian, Wang, Wang and Chu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Abudoureyimu, Mubalake
Lai, Yongting
Tian, Chuan
Wang, Ting
Wang, Rui
Chu, Xiaoyuan
Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
title Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
title_full Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
title_fullStr Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
title_full_unstemmed Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
title_short Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
title_sort oncolytic adenovirus—a nova for gene-targeted oncolytic viral therapy in hcc
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857090/
https://www.ncbi.nlm.nih.gov/pubmed/31781493
http://dx.doi.org/10.3389/fonc.2019.01182
work_keys_str_mv AT abudoureyimumubalake oncolyticadenovirusanovaforgenetargetedoncolyticviraltherapyinhcc
AT laiyongting oncolyticadenovirusanovaforgenetargetedoncolyticviraltherapyinhcc
AT tianchuan oncolyticadenovirusanovaforgenetargetedoncolyticviraltherapyinhcc
AT wangting oncolyticadenovirusanovaforgenetargetedoncolyticviraltherapyinhcc
AT wangrui oncolyticadenovirusanovaforgenetargetedoncolyticviraltherapyinhcc
AT chuxiaoyuan oncolyticadenovirusanovaforgenetargetedoncolyticviraltherapyinhcc